Latest Conference Articles

Daratumumab combined with VRd significantly improved outcomes in transplant-ineligible/transplant deferred patients with newly diagnosed multiple myeloma.

Epcoritamab shows impressive long-term remission rates in relapsed large B-cell lymphoma, highlighting its potential as a key treatment option.

Alice H. Lichtenstein, DSc, emphasizes the importance of whole-food dietary patterns over macronutrient percentages for improving lipid profiles and cardiovascular health.

Pre-treatment DPYD genotyping significantly reduces hospitalizations and costs for patients with cancer, enhancing safety and efficiency in oncology care.

Grace Nguyen, PharmD, BCPS, provides real-world experiences with DPYD genotype-guided fluoropyrimidine dosing, highlighting how pharmacist-led interventions and tailored dose adjustments can help mitigate toxicity risks and optimize treatment in variant carriers.

The data from the phase 3 SEQUOIA study are to be presented at the 2025 ASCO Annual Meeting.

Imetelstat shows promise in treating myelofibrosis, enhancing survival, and modifying disease biology in patients resistant to JAK inhibitors.

Christian John Lillis reflects on key insights from the 2025 Peggy Lillis Foundation C diff Summit, highlighting the critical role of pharmacists in infectious disease care, persistent challenges in patient outcomes, and the need for renewed investment in public health infrastructure and policy.

Christian John Lillis discusses the 2025 Peggy Lillis Foundation C diff Summit, emphasizing the enduring need for community-building among survivors, the importance of sustained public health advocacy, and the growing urgency to defend federal health agencies amid political and institutional uncertainty.

In a session at the 2025 Virtual Conference on Pain and Palliative Care, Isabella Zerfas, PharmD, and Abbey Galligan, PharmD, BCPS, explore effective pain management strategies for opioid use disorder (OUD) and complex persistent opioid dependence.

Experts emphasize the importance of tailored vaccination strategies for pneumococcal based on individual risk factors.

RSV vaccination for older adults requires understanding risk factors, using empathetic communication strategies, and proactively identifying eligible patients through careful review of medical histories and care transitions.

Don Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, received a leadership award at the 2025 HOPA Annual Meeting.

Logan Schneider, MD, highlights the importance of integrating patient-reported outcomes into clinical trials to better capture the full therapeutic impact of low-sodium oxybate (Xywav) beyond traditional sleep metrics.

Emma Murter, PharmD, MPH, and Madison N. Irwin, PharmD, BCPS, discuss the potential role of low-dose naltrexone in managing chronic pain in palliative care, highlighting its anti-inflammatory properties, limited adverse effects, and current evidence gaps—particularly in comparison to traditional opioids and adjuvant analgesics.

Specialty pharmacy experts and key opinion leaders gathered at Asembia’s AXS25 Summit and discussed critical insights in interviews with Pharmacy Times®.

Lacy La Fever, PharmD, MS, discussed outcomes associated with different carboplatin AUC dosing strategies.

Specialty pharmacy experts discuss how emotional support, addressing patient loneliness, and peer-to-patient programs can significantly improve medication adherence and patient care.

Experts emphasized the importance of addressing regulatory and payer-side challenges to fully leverage AI's potential in pharmacy settings.

Digital pharmacy solutions are revolutionizing patient care.

One dose of the vaccine compared with 2 may help increase global HPV vaccine uptake.

Abigail Thomas, PharmD, and Lee A. Kral, PharmD, discuss the evolving role of psilocybin-assisted therapy in palliative care, highlighting current evidence, safety concerns, and how pharmacists can guide patient selection, manage drug interactions, and support education as the therapy moves closer to clinical use.

A recent study reveals a significant number of patients with psychiatric histories experience emergency visits after starting glucagon-like peptide-1 (GLP-1) medications, raising safety concerns.

Diana Violanti, PharmD, and Pamela S. Moore, PharmD, BCGP, discuss the nuanced use of anticholinergic agents for managing terminal secretions at end of life, highlighting practical considerations, timing, safety concerns such as delirium, and the limited yet evolving evidence supporting their role in palliative care.

Cardinal Health is investing in cold chain logistics and packaging solutions to expedite the delivery of novel therapies from FDA approval to patient access.

New trials reveal xanomeline and trospium effectively alleviate schizophrenia symptoms, offering a novel treatment option with minimal adverse effects.